GS-248 is under clinical development by Gesynta Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GS-248’s likelihood of approval (LoA) and phase transition for Raynauds Disease took place on 04 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 04 Aug 2022 increased GS-248’s Phase Transition Success Rate (PTSR) for Systemic Sclerosis (Scleroderma).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GS-248 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GS-248 overview

GS-248 (OX-MPI) is under development for the treatment of Raynaud's disease (microvascular disease) and systemic sclerosis. It is microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor. It is administered through the oral route.

Gesynta Pharma overview

Gesynta Pharma (Gesynta) is a biopharmaceutical company that develops drugs for the treatment of microvascular disease in chronic inflammatory conditions. It specializes in arachidonic acid research to analyze anti-inflammatory and vasoprotective effects in cardiovascular diseases and cancer. Gesynta is headquartered in Solna, Stockholm, Sweden.

Quick View GS-248 LOA Data

Report Segments
  • Innovator
Drug Name
  • GS-248
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Immunology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.